首页>
外国专利>
Double price slide with CD123 and CD3 and its application
Double price slide with CD123 and CD3 and its application
展开▼
机译：CD123和CD3的双重价格下滑及其应用
展开▼
页面导航
摘要
著录项
相似文献
摘要
Requirement 1: an optimized sequence, which can be specifically linked to the CD123 title and CD3 title, is marked by that the body includes the first polypeptide chain and the second polypeptide chain, which are covalently linked,Among them: (a) the first polypeptide chain at the N-terminal a-c-terminal address: 1) includes (1) a subfield (1a),a. The VL domain (SEQ ID No. 21) includes a monoclonal antibody that can connect CD3 (vlcd832323);And (2) a subdomain (1b),comprising a VH Domain of a monoclonal antibody capable of binding to CD123 (VHCD₁₂₃) (SEQ ID No. 26),a. 1A and 1B are separated by a peptide can (SEQ ID No.29);ii) a Domain 2, where Domain 2 is a Domain with Spiral E (SEQ ID No. 34) or a Domain with spiral K (SEQ ID No. 35),2. Separate field 2 from field 1 through a peptide can (SEQ ID No.30);(b) In the direction of N-terminal a-c-terminal, the second polypeptide chain includes a domain name 1, including (1) a subdomain name (1a),comprising a VL Domain of a monoclonal antibody capable of binding to CD123 (VLCD₁₂₃) (SEQ ID No. 25);And (2) a subdomain (1b),The VH feature (SEQ ID No.22) of a monoclonal antibody capable of connecting CD3 (vhcd832323) is included,a. 1A and 1B are separated from each other by a peptide can (SEQ ID No.29);ii) a Domain 2, where Domain 2 is a Domain with spiral K (SEQ ID No. 35) or a Domain with Spiral E (SEQ ID No. 34),2. Separate field 2 from field 1 through a peptide can (SEQ ID No.30);However, in the field of the first and second polypeptide chains, 2 is not two helix e domains or two helix K domains, where: (a) the VL domain of the first polypeptide chain and the VH domain of the second polypeptide chain form an antigen linking domain that can be specifically connected to CD3 entry; and (b) the VL domain of the second polypeptide chain and the VH domain of the first polypeptide chain form an antigen linked domain that can specifically link to the CD123 entry. Requirement 15: drug composition,It is characterized by including any one of 1 to 8 requirements and a physiologically acceptable carrier. Claim 16: the use of a pharmaceutical ingredient according to claim 15, characterized by its use in the treatment of a disease or condition related to or represented by the expression of CD123. Claim 20: use in accordance with claim 19, wherein the flammability condition is selected from the following groups: autoimmune lupus erythematosus (SLE),Allergies and asthma.
展开▼
机译：要求1：可以与CD123标题和CD3标题特异性连接的优化序列，其特征是该主体包括共价连接的第一条多肽链和第二条多肽链，其中：（a）第一条N末端ac末端的多肽链：1）包括（1）子域（1a），a。 VL结构域（SEQ ID No.21）包括一个可以连接CD3的单克隆抗体（vlcd832323）;以及（2）一个亚结构域（1b），包括一个能够与CD123（VHCD 12+）结合的单克隆抗体的VH结构域（SEQ编号26），a。 1A和1B被肽罐（SEQ ID No.29）分开; ii）结构域2，其中结构域2是具有螺旋E的结构域（SEQ ID No.34）或具有螺旋K的结构域（SEQ ID No.29）。 35），2。通过肽罐（SEQ ID No.30）将字段2与字段1分开;（b）在N端ac端的方向上，第二条多肽链包含一个域名1，其中包括（1）一个亚域名（ 1a），包含能够结合CD123的单克隆抗体的VL结构域（VLCD 12）（SEQ ID No. 25）;和（2）亚结构域（1b），VH特征（SEQ ID No. 22）包含能够连接CD3的抗体（vhcd832323） 1A和1B通过肽罐（SEQ ID No.29）彼此分开; ii）结构域2，其中结构域2是具有螺旋K的结构域（SEQ ID No.35）或具有螺旋E的结构域（SEQ ID No.35）编号34），2。通过肽罐将字段2与字段1分开（SEQ ID No.30）;但是，在第一条和第二条多肽链的字段中，2不是两个螺旋e结构域或两个螺旋K结构域，其中：（a）第一多肽链的VL结构域和第二多肽链的VH结构域形成抗原连接结构域，其可以特异性地连接至CD3进入。 （b）第二条多肽链的VL结构域和第一条多肽链的VH结构域形成抗原特异性连接结构域，其可以特异性地连接至CD123入口。要求15：药物组合物，其特征在于包括1至8个要求中的任一项和生理上可接受的载体。权利要求16：根据权利要求15的药物成分的用途，其特征在于其在治疗与CD123表达有关或由其表达的疾病或病症中的用途。 20.根据权利要求19所述的用途，其中所述可燃性状况选自以下组：自身免疫性红斑狼疮（SLE），过敏和哮喘。
展开▼
